readthroughSign in
CompanyANLNasdaqSingapore

Adlai Nortye Group Ltd.

Adlai Nortye develops cancer therapies including the oral pan-RAS inhibitor AN9025, the CEACAM5-targeting antibody-drug conjugate AN4035, and AN8025, a PD-1/L1 pathway fusion protein.

10-QNov 13Latest SEC filing
Oct 28Latest story